Editorial Staff

Editor Barbara Zeiger

Assistant Editor Lauren Mateja

Web Content Coordinator Katherine Blessing

Editorial Correspondence

Barbara Zeiger, Editor, OWM

HMP Communications, 70 E Swedesford Rd
Suite 100, Malvern PA, 19355

Telephone: (800) 237-7285 or
(610) 560-0500, ext. 4244
Fax: (610) 560-0501

Email: bzeiger@hmpcommunications.com

June 2015 ISN 1943-2720 | Volume 61 - Issue 6

The Prevalence of Anemia of Chronic Disease in Patients With Spinal Cord Injuries and Pressure Ulcers and the Impact of Erythropoietin Supplementation on Wound Healing: A Descriptive Pilot Study


    Anemia of chronic disease (ACD) is thought to impair the responsiveness of erythroid progenitor cells, but research has shown treatment with recombinant human erythropoietin (rhuEPO) can improve patient hemoglobin levels and, subsequently, overall patient health status and quality of life. A prospective pilot study was designed to estimate the prevalence of ACD in outpatients with spinal cord injury (SCI) and chronic pressure ulcers (PUs) and examine the impact of rhuEPO on PU healing in this population. The charts of 49 SCI patients with PUs were reviewed; of those, 17 had anemia (hemoglobin <110 g/L). The prevalence of anemia in SCI patients with PUs was found to be approximately 35%....

Implementing a Pro-forma for Multidisciplinary Management of an Enterocutaneous Fistula: A Case Study


    Optimal management of patients with an entercocutaneous fistula (ECF) requires utilization of the sepsis, nutrition, anatomy, and surgical procedure (SNAP) protocol. The protocol includes early detection and treatment of sepsis, optimizing patient nutrition through oral and parenteral routes, identifying the fistula anatomy, optimal fistula management, and proceeding to corrective surgery when appropriate. The protocol requires multidisciplinary team (MDT) coordination among surgeons, nurses, dietitians, stoma nurses, and physiotherapists. ...

Hypertonic Glucose Combined with Negative Pressure Wound Therapy to Prepare Wounds with Pseudomonas aeruginosa Infection for Skin Grafting: A Report of 3 Cases


    Soft tissue losses from acute or chronic trauma are a challenge for surgeons. To explore a method to expedite granulation tissue formation in preparation for a split-thickness skin graft (STSG), the medical records of 3 patients — 2 adult men with wounds related to trauma injury and 1 infant with necrotizing fasciitis, all infected with Pseudomonas aeruginosa — were reviewed. All wounds were surgically debrided and managed by applying gauze soaked in 50% glucose followed by continuous negative pressure wound therapy (NPWT) before definitive skin grafting. ...

Special to OWM: Abrupt CMS Decision May Threaten Hundreds of Thousands of Wound Care Patients with Potential Limb Loss

    A safe and effective therapy for persons with a chronic wound — a condition with a higher mortality rate than many cancers and that can lead to amputation, impact quality of life, impair mobility, and negatively affect family and caregivers — is no longer covered by Medicare. ...

A Clinical Minute: Managing Skin Tears With MEDIHONEY®

    In the hospital or long-term care setting, clinicians will see skin tears in all shapes, sizes, and etiologies. As with pressure ulcers, the aim is to prevent them. But when they occur, skin tears are painful for the patient, challenging to treat, and can open the door to other problems such as infection and delayed wound healing. Having a skin tear dressing protocol and dressing application training in place for staff is essential to getting everyone on the same page....

Editor’s Opinion: Progress: Baby Steps Yield Leaps and Bounds

    Clinicians know they must answer 3 questions before implementing any intervention: 1) Can it work? 2) Does it work? 3) Is it worth it?1 Most issues of Ostomy Wound Management contain preclinical and clinical reports that attempt to answer the first of these questions. For the clinician looking for information and guidance in the literature, it may be disheartening to realize a study does not provide solid answers to the second or third question and yield ready-to-use results. In fact, many studies only answer part of the first question using in vivo or in vitro research methodologies — baby steps toward the ultimate goal of implementing care that is efficacious, effective, and cost effective....

My Scope of Practice: A Recipe for WOC Care

Somebody said that it couldn’t be done
But he with a chuckle replied
That “maybe it couldn’t,” but he would be one
Who wouldn’t say so till he’d tried.
So he buckled right in with a trace of a grin
On his face. If he worried he hid it.He started to sing as he tackled the thing
That couldn’t be done, and he did it. — It Couldn’t Be Done by Edgar Albert Guest...

Industry News

Microsize bladder device receives FDA IDE designation

    StimGuard (Ft. Lauderdale, FL), a privately-held, precommercial stage medical device company, received US Food and Drug Administration Investigational Device Exemption approval to launch a clinical trial of the world’s first passive microsize implantable device for the treatment of overactive bladder syndrome, utilizing wireless technology and placed completely through a needle. The clinical trial will launch in summer 2015....


Wound-care Experts/FDA — Clinical Endpoints Project (WEF-CEP)

    Currently, the only wound care endpoint recognized by the United States Food and Drug Administration (FDA) in determining device, drug, and therapy approvals is full wound closure. Clinical experts, including members of the AAWC, saw the need to work with the FDA to determine additional clinical endpoints; thus, the Wound-care Experts/FDA — Clinical Endpoints Project (WEF-CEP) was developed last year. The AAWC is the host of the project and the Wound Healing Society is cohost. This is a specific, collaborative effort with the FDA to determine scientifically rigorous yet achievable clinical endpoints to facilitate device and new drug development activities to help heal difficult wounds....